Viva Biotech Holdings announced that its wholly-owned subsidiary, Viva Incubator, has agreed to dispose of its minority equity interest in Arthrosi Therapeutics. The transaction will occur through a merger in which Sobi US Holding Corp. will acquire Arthrosi Therapeutics. Under the terms of the merger agreement, Viva Biotech Holdings will receive an upfront payment of US$950 million at closing, subject to customary adjustments, and may receive additional contingent consideration of up to US$550 million. Following the completion of the merger, Viva Biotech Holdings will no longer hold any equity interest in Arthrosi Therapeutics.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VIVA Biotech Holdings published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251214-11954807), on December 14, 2025, and is solely responsible for the information contained therein.